LSE - Delayed Quote USD

ResMed Inc. (0KW4.L)

213.58

+0.96

+(0.45%)

At close: 6:04:11 PM GMT+1

What Analyst Projections for Key Metrics Reveal About ResMed (RMD) Q3 Earnings

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for ResMed (RMD), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended March 2025.

Zacks 6 hours ago

RMD
ResMed (RMD) Reports Next Week: Wall Street Expects Earnings Growth

ResMed (RMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks yesterday

RMD

RSMDF
Here's Why ResMed (RMD) is a Strong Growth Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks 2 days ago

RMD
ResMed's Fiscal Q3 Likely to Meet Consensus Estimates; Faces Supply Chain Risks, UBS Says

ResMed's (RMD) fiscal Q3 is likely to meet consensus estimates, but the company is facing potential

PREMIUM
MT Newswires 8 days ago

RMD
Strength Seen in ResMed (RMD): Can Its 3.8% Jump Turn into More Strength?

ResMed (RMD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks 9 days ago

RMD

AHCO
Q4 Patient Monitoring Earnings Review: First Prize Goes to Masimo (NASDAQ:MASI)

Let’s dig into the relative performance of Masimo (NASDAQ:MASI) and its peers as we unravel the now-completed Q4 patient monitoring earnings season.

StockStory 9 days ago

MASI

IRTC

DXCM
ResMed (NYSE:RMD) Launches NightOwl Device to Simplify Home Sleep Apnea Testing Across US

ResMed (NYSE:RMD) launched NightOwl™, a home sleep apnea test that enhances user convenience with a small fingertip sensor and cloud data evaluation. Despite the broader market reacting negatively to new tariffs announced by President Trump—causing significant declines across major indexes like the Dow Jones and S&P 500—ResMed's stock remained relatively flat over the past week. The stable performance may reflect investor confidence in the potential of its innovative health solutions,...

Simply Wall St. 14 days ago

RMD

RSMDF
ResMed Inc. (RMD): A Bull Case Theory

We came across a bullish thesis on ResMed Inc. (RMD) on Substack by LongTermValue Research. In this article, we will summarize the bulls’ thesis on RMD. ResMed Inc. (RMD)’s share was trading at $223 as of April 2nd. RMD’s trailing and forward P/E were 26.33 and 21.79 respectively according to Yahoo Finance. ResMed (RMD), a $32.5 billion […]

Insider Monkey 14 days ago

RMD
Resmed Announces Small, Easy to Use Home Sleep Apnea Test, NightOwl™, Now Available Across the US

FDA-cleared home sleep test provides an effective and simplified solution to obstructive sleep apnea testing and diagnosisSAN DIEGO, April 03, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing, and care delivered in the home, today announced its home sleep apnea test, NightOwl™, is now available across the United States. NightOwl is an FDA-cleared home sleep apnea test (HSAT) designed to offer healthcare providers a simplifie

GlobeNewswire 14 days ago

RMD

RSMDF
Resmed Inc. (RMD): Jim Cramer Says He Likes This Sleep Apnea Treatment Stock

We recently published a list of Jim Cramer is Discussing These 10 Stocks Ahead of Q1 Earnings Season. In this article, we are going to take a look at where Resmed Inc. (NYSE:RMD) stands against other stocks that Jim Cramer is discussing ahead of Q1 earnings season. Jim Cramer in a latest program on CNBC […]

Insider Monkey 14 days ago

RMD
Resmed to Report Third Quarter Fiscal 2025 Earnings on April 23, 2025

SAN DIEGO, April 02, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the third quarter of fiscal year 2025 on Wednesday, April 23, 2025, after the New York Stock Exchange closes. Following the release, Resmed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast. Earnings webcast details: •Location:https://investor.resmed.com •Da

GlobeNewswire 14 days ago

RMD

RSMDF
Morgan Stanley Sees Near-Term Rally Ahead — Here Are 2 Stocks to Bet on It

Markets have proven highly volatile in the first two months of President Trump’s new term of office, as investors are worried about everything from trade and tariff policy to increased inflation to geopolitics. But there are some green lights flashing on the market dashboard. For starters, the prices of some staple goods are coming down – prices are dropping for both gasoline and eggs, for instance – and in the past two weeks, markets have turned back upward. Covering the market situation from M

TipRanks 20 days ago

RMD

RSMDF

CVNA
Jim Cramer On ResMed Inc. (RMD) – “I’m With Mick! ResMed’s Doing Quite Well”

We recently published a list of Jim Cramer Recently Talked About These 12 Companies. In this article, we are going to take a look at where ResMed Inc. (NYSE:RMD stands against other stocks that Jim Cramer discussed recently. Jim Cramer, host of Mad Money, warned investors on Friday that until there is more clarity regarding […]

Insider Monkey 22 days ago

RMD
ResMed initiated with an Overweight at Morgan Stanley

Morgan Stanley analyst David Bailey initiated coverage of ResMed (RMD) with an Overweight rating and $280 price target The company has a market-leading position in the obstructive sleep apnea market and valuations appear attractive at current levels, with a strong balance sheet position and the highest ROIC across the firm’s Australian Healthcare industry sector coverage, the analyst tells investors. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial

TipRanks 28 days ago

RMD

RSMDF
New Global Study Finds: Sleep Apnea Patients Who Use CPAP Live Longer

Largest ever meta-analysis on the long-term benefits of CPAP therapy, published in The Lancet Respiratory Medicine, found that in people with sleep apnea, CPAP therapy lowered the overall chance of dying by 37% and the chance of heart-related death by 55%.SAN DIEGO, March 19, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the global leader in health technology focused on sleep, breathing, and care delivered in the home, today announced the publication of a landmark meta-analysis in The L

GlobeNewswire 29 days ago

RMD

RSMDF
New Product Launches Benefit GMED Stock Amid Macro Issues

Globus Medical currently awaits a strong cadence of product launches throughout the Musculoskeletal portfolio in the coming months of 2025.

Zacks 30 days ago

GMED

RMD
Why ResMed (RMD) is a Top Growth Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks last month

RMD
The Zacks Analyst Blog Highlights NVIDIA, Resmed, GE HealthCare and Medtronic

NVIDIA, Resmed, GE HealthCare and Medtronic are part of the Zacks top Analyst Blog.

Zacks last month

NVDA

MDT

RMD
NVIDIA's AI Speeds Up MedTech's Digital Boom: 3 Stocks in Focus

RMD, GEHC and MDT are expected to thrive as NVIDIA and other AI leaders' MedTech ventures accelerate digital adoption within the space.

Zacks last month

NVDA

MDT

RMD
RMD Stock Likely to Benefit From the New Brand Evolution Strategy

In another major brand update, Resmed is likely to unify all the brands under one identity.

Zacks last month

RMD

CAH

Performance Overview

Return	0KW4.L	MSCI WORLD (^990100-USD-STRD)
YTD	-6.41%	-6.10%
1-Year	+15.92%	+6.11%
3-Year	-6.98%	0.00%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

ResMed Inc. (0KW4.L)

What Analyst Projections for Key Metrics Reveal About ResMed (RMD) Q3 Earnings

ResMed (RMD) Reports Next Week: Wall Street Expects Earnings Growth

Here's Why ResMed (RMD) is a Strong Growth Stock

ResMed's Fiscal Q3 Likely to Meet Consensus Estimates; Faces Supply Chain Risks, UBS Says

Strength Seen in ResMed (RMD): Can Its 3.8% Jump Turn into More Strength?

Q4 Patient Monitoring Earnings Review: First Prize Goes to Masimo (NASDAQ:MASI)

ResMed (NYSE:RMD) Launches NightOwl Device to Simplify Home Sleep Apnea Testing Across US

ResMed Inc. (RMD): A Bull Case Theory

Resmed Announces Small, Easy to Use Home Sleep Apnea Test, NightOwl™, Now Available Across the US

Resmed Inc. (RMD): Jim Cramer Says He Likes This Sleep Apnea Treatment Stock

Resmed to Report Third Quarter Fiscal 2025 Earnings on April 23, 2025

Morgan Stanley Sees Near-Term Rally Ahead — Here Are 2 Stocks to Bet on It

Jim Cramer On ResMed Inc. (RMD) – “I’m With Mick! ResMed’s Doing Quite Well”

ResMed initiated with an Overweight at Morgan Stanley

New Global Study Finds: Sleep Apnea Patients Who Use CPAP Live Longer

New Product Launches Benefit GMED Stock Amid Macro Issues

Why ResMed (RMD) is a Top Growth Stock for the Long-Term

The Zacks Analyst Blog Highlights NVIDIA, Resmed, GE HealthCare and Medtronic

NVIDIA's AI Speeds Up MedTech's Digital Boom: 3 Stocks in Focus

RMD Stock Likely to Benefit From the New Brand Evolution Strategy

Performance Overview